映恩生物-B(09606)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09606 映恩生物-B

已收盘 07-29 16:08:27

368.000

+7.800

+2.17%

最高370.400	最低352.200	成交量22.05万
今开370.000	昨收360.200	日振幅5.05%
总市值323.97亿	流通市值323.97亿	总股本8,804万
成交额8,050万	换手率0.25%	流通股本8,804万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09606","market":"HK","secType":"STK","nameCN":"映恩生物-B","latestPrice":368,"timestamp":1753776507373,"preClose":360.2,"halted":0,"volume":220495,"delay":0,"floatShares":88036299,"shares":88036299,"eps":-143.52565922520782,"marketStatus":"已收盘","change":7.8,"latestTime":"07-29 16:08:27","open":370,"high":370.4,"low":352.2,"amount":80502271,"amplitude":0.050527,"askPrice":368.4,"askSize":300,"bidPrice":368,"bidSize":100,"shortable":0,"etf":0,"ttmEps":-143.52567015597893,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1753839000000},"marketStatusCode":5,"adr":0,"listingDate":1744646400000,"exchange":"SEHK","adjPreClose":360.2,"openAndCloseTimeList":[[1753752600000,1753761600000],[1753765200000,1753776000000]],"volumeRatio":1.101048,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09606","defaultTab":"news","newsList":[{"id":"2555059241","title":"映恩生物-B07月29日主力净流入398.3万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2555059241","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555059241?lang=zh_cn&edition=full","pubTime":"2025-07-29 16:15","pubTimestamp":1753776940,"startTime":"0","endTime":"0","summary":"07月29日, 映恩生物-B股价涨2.17%，报收368.00元，成交金额8050.2万元，换手率0.25%，振幅5.05%，量比1.10。映恩生物-B今日主力资金净流入398.3万元，上一交易日主力净流出128.1万元。该股近5个交易日上涨12.09%，主力资金累计净流入487.5万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入1629.7万元，其中净流入天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250729165711a46952e9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250729165711a46952e9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09606","BK1161"],"gpt_icon":0},{"id":"2553919402","title":"1500万美元首付款，又一款国产CAR-T出海；赛诺菲16亿美元收购疫苗企业","url":"https://stock-news.laohu8.com/highlight/detail?id=2553919402","media":"Ofweek光电信息网","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553919402?lang=zh_cn&edition=full","pubTime":"2025-07-23 14:02","pubTimestamp":1753250520,"startTime":"0","endTime":"0","summary":"又一款国产创新药出海。科弈药业将获1500万美元近期里程碑付款。赛诺菲不强疫苗版图。/ 03 / 海外药闻1）赛诺菲16亿美元收购疫苗企业7月22日， 赛诺菲宣布收购总部位于英国伦敦的生物技术公司Vicebio。根据协议条款，赛诺菲将以总计11.5亿美元的预付款项收购Vicebio的全部股本，并根据开发和监管里程碑的实现情况支付最高达4.5亿美元的潜在里程碑款项。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072314243797b1e551&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072314243797b1e551&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688351","09606","BK1161"],"gpt_icon":0},{"id":"2553283682","title":"港股异动 | 映恩生物-B(09606)涨超4%再创新高 关键产品DB-1310获美国FDA授予快速通道资格认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2553283682","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553283682?lang=zh_cn&edition=full","pubTime":"2025-07-22 10:06","pubTimestamp":1753149985,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，映恩生物-B涨超4%，高见347港元，再创上市新高。消息面上，映恩生物公布，公司的关键产品DB-1310(一款靶向人表皮生长因子受体3(HER3)的抗体偶联药物(ADC”)已获美国食品药品监督管理局(FDA)授予快速通道资格认定，用于治疗接受第三代表皮生长因子受体(EGFR)酪氨酸激酶抑制剂(TKI)治疗和含铂化疗治疗期间或之后疾病进展、携带EGFR 19外显子缺失或L858R突变的晚期╱不可切除或转移性非鳞状非小细胞肺癌(nsqNSCLC)成人患者。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1320388.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK4552","09606","BK4566","DB","BK4118","BK4588","BK4585"],"gpt_icon":0},{"id":"2553402702","title":"映恩生物宣布DB管线取得重大进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2553402702","media":"DoNews","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553402702?lang=zh_cn&edition=full","pubTime":"2025-07-22 07:44","pubTimestamp":1753141442,"startTime":"0","endTime":"0","summary":"映恩生物近日宣布，其研发中的DB管线药物已完成临床前研究，并即将进入临床试验阶段。该管线针对特定肿瘤适应症，展现出良好的靶点特异性和潜在治疗优势。目前，映恩生物正按计划推进DB管线的IND申报相关工作，预计在2025年内完成并向监管机构提交申请。此次进展标志着公司在创新生物药研发领域迈出关键一步。映恩生物首席科学官表示，DB管线的成功开发将有助于丰富公司在肿瘤治疗领域的布局，并为未来产品组合提供更多支持。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072207461697af89c8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072207461697af89c8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09606","BK1161"],"gpt_icon":0},{"id":"2553404177","title":"映恩生物-B关键产品DB-1310获美国FDA授予快速通道资格认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2553404177","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553404177?lang=zh_cn&edition=full","pubTime":"2025-07-22 06:22","pubTimestamp":1753136573,"startTime":"0","endTime":"0","summary":"智通财经APP讯，映恩生物-B 公布，公司的关键产品DB-1310(一款靶向人表皮生长因子受体3(HER3)的抗体偶联药物(ADC”)已获美国食品药品监督管理局(FDA)授予快速通道资格认定，用于治疗接受第三代表皮生长因子受体(EGFR)酪氨酸激酶抑制剂(TKI)治疗和含铂化疗治疗期间或之后疾病进展、携带EGFR 19外显子缺失或L858R突变的晚期╱不可切除或转移性非鳞状非小细胞肺癌(nsqNSCLC)成人患者。据悉，FDA快速通道资格认定是一种加速开发和审批潜在药物的方法。","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1320306.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK4118","BK4552","BK4566","BK1161","09606","BK4585","DB"],"gpt_icon":0},{"id":"2552460194","title":"司美格鲁肽慢性肾病适应症在国内获批；首个重组人血清白蛋白上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2552460194","media":"氨基观察","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552460194?lang=zh_cn&edition=full","pubTime":"2025-07-18 19:04","pubTimestamp":1752836640,"startTime":"0","endTime":"0","summary":"白蛋白市场迎来新选手。该药物是我国首个获批上市的重组人血清白蛋白产品。9）诺和诺德司美格鲁肽获批治疗慢性肾病7月18日，据 NMPA官网，诺和诺德司美格鲁肽注射液获批新适应症，用于降低2型糖尿病合并慢性肾病成人患者因心血管疾病而恶化、肾衰竭和死亡的风险。该适应症已在今年1月获FDA批准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250718193709a453738b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250718193709a453738b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["00853","09606","BK1589","06998","BK1583","BK1585","BK1100","09995","01801"],"gpt_icon":0},{"id":"2552543546","title":"映恩生物-B07月17日主力净流入777.4万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2552543546","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552543546?lang=zh_cn&edition=full","pubTime":"2025-07-17 16:15","pubTimestamp":1752740124,"startTime":"0","endTime":"0","summary":"07月17日, 映恩生物-B股价涨5.73%，报收328.40元，成交金额1.6亿元，换手率0.54%，振幅8.31%，量比2.44。映恩生物-B今日主力资金净流入777.4万元，上一交易日主力净流出291.8万元。该股近5个交易日上涨14.73%，主力资金累计净流入604.6万元；近20日主力资金累计净流出341.7万元，其中净流出天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717170946a6af67c8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717170946a6af67c8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","09606"],"gpt_icon":0},{"id":"1126684543","title":"港股创新药概念股持续上攻，康方生物等多股创历史新高","url":"https://stock-news.laohu8.com/highlight/detail?id=1126684543","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126684543?lang=zh_cn&edition=full","pubTime":"2025-07-17 09:39","pubTimestamp":1752716365,"startTime":"0","endTime":"0","summary":"7月17日，港股创新药概念股延续强势，$康方生物(09926)$涨超8%，$三生制药(01530)$、$乐普生物-B(02157)$涨超6%，$亚盛医药-B(06855)$涨超5%。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B543WZ88.USD","09606","BK1593","LU0348783233.USD","LU0348784397.USD","LU0417516571.SGD","LU1794554557.SGD","LU2488822045.USD","IE00B5MMRT66.SGD","09926","IE00BPRC5H50.USD","01530","BK1161","BK1574","LU1720050803.USD","BK1583","BK4614"],"gpt_icon":0},{"id":"1178832126","title":"映恩生物-B股价刷上市新高，该股上市以来累涨225%","url":"https://stock-news.laohu8.com/highlight/detail?id=1178832126","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178832126?lang=zh_cn&edition=full","pubTime":"2025-07-16 10:27","pubTimestamp":1752632860,"startTime":"0","endTime":"0","summary":"7月16日，$映恩生物-B(09606)$再涨3%！高见309.6港元刷上市新高，该股上市以来累涨225%。","market":"hk","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"gpt_icon":0},{"id":"2551508241","title":"映恩生物-B07月15日获主力加仓48.4万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2551508241","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551508241?lang=zh_cn&edition=full","pubTime":"2025-07-15 16:16","pubTimestamp":1752567368,"startTime":"0","endTime":"0","summary":"07月15日, 映恩生物-B股价涨4.02%，报收300.20元，成交金额3978.2万元，换手率0.15%，振幅6.72%，量比0.57。映恩生物-B今日主力资金净流入48.4万元，上一交易日主力净流入70.7万元。该股近5个交易日上涨6.08%，主力资金累计净流入862.4万元；近20日主力资金累计净流入693.6万元，其中净流入天数为7日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250715170220a6aabc35&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250715170220a6aabc35&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","09606"],"gpt_icon":0},{"id":"2551147901","title":"映恩生物-B07月14日主力净流入70.7万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2551147901","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551147901?lang=zh_cn&edition=full","pubTime":"2025-07-14 16:15","pubTimestamp":1752480959,"startTime":"0","endTime":"0","summary":"07月14日, 映恩生物-B股价涨0.28%，报收288.60元，成交金额4434.4万元，换手率0.18%，振幅4.79%，量比0.67。映恩生物-B今日主力资金净流入70.7万元，上一交易日主力净流出0万元。该股近5个交易日上涨4.95%，主力资金累计净流入814.0万元；近20日主力资金累计净流入477.4万元，其中净流入天数为6日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714171035a4498089&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714171035a4498089&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","09606"],"gpt_icon":0},{"id":"2550268733","title":"映恩生物-B07月09日主力净流入894.9万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2550268733","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550268733?lang=zh_cn&edition=full","pubTime":"2025-07-09 16:15","pubTimestamp":1752048927,"startTime":"0","endTime":"0","summary":"07月09日, 映恩生物-B股价涨6.22%，报收300.60元，成交金额1.1亿元，换手率0.44%，振幅7.07%，量比1.51。映恩生物-B今日主力资金净流入894.9万元，上一交易日主力净流出0万元。该股近5个交易日上涨26.30%，主力资金累计净流入837.7万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入639.2万元，其中净流入天数为7日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709165400a43ff0cf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709165400a43ff0cf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09606","BK1161"],"gpt_icon":0},{"id":"2548443800","title":"映恩生物-B07月03日主力净流入202.6万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2548443800","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548443800?lang=zh_cn&edition=full","pubTime":"2025-07-03 16:15","pubTimestamp":1751530533,"startTime":"0","endTime":"0","summary":"07月03日, 映恩生物-B股价涨9.24%，报收260.00元，成交金额7866.2万元，换手率0.35%，振幅12.18%，量比1.29。映恩生物-B今日主力资金净流入202.6万元，上一交易日主力净流出221.3万元。该股近5个交易日上涨5.52%，主力资金累计净流出627.7万元；近20日主力资金累计净流入1466.1万元，其中净流入天数为7日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250703170143a4ccfae4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250703170143a4ccfae4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","09606"],"gpt_icon":0},{"id":"2548852360","title":"【券商聚焦】华泰证券：19只个股9月或将被纳入港股通范围","url":"https://stock-news.laohu8.com/highlight/detail?id=2548852360","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548852360?lang=zh_cn&edition=full","pubTime":"2025-07-02 13:49","pubTimestamp":1751435347,"startTime":"0","endTime":"0","summary":"因此，海天味业、三花智控对应港股入通时间更早，将分别于7月17日、7月21日纳入港股通。南向资金在香港市场的重要性的持续提升，或进一步放大本轮港股通标的调整带来的流动性效应。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250702135508a729dd3c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250702135508a729dd3c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["07226","HSCEI","09606","09678","BK1116","06886","HSTECH","BK1564","02609","BK1147","01729","02610"],"gpt_icon":0},{"id":"2546213941","title":"映恩生物-B06月25日遭主力抛售395.5万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2546213941","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2546213941?lang=zh_cn&edition=full","pubTime":"2025-06-25 16:15","pubTimestamp":1750839322,"startTime":"0","endTime":"0","summary":"06月25日, 映恩生物-B股价跌2.99%，报收246.20元，成交金额5169.9万元，换手率0.24%，振幅4.96%，量比1.10。映恩生物-B今日主力资金净流出395.5万元，连续3日净流出，上一交易日主力净流出218.4万元。该股近5个交易日下跌4.22%，主力资金累计净流出802.2万元，其中2个交易日为股价上涨时净流出；近20日主力资金累计净流入2609.0万元，其中净流入天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250625172536a71cc618&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250625172536a71cc618&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","09606"],"gpt_icon":0},{"id":"2543789476","title":"映恩生物-B06月16日主力净流出167.7万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2543789476","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2543789476?lang=zh_cn&edition=full","pubTime":"2025-06-16 16:15","pubTimestamp":1750061708,"startTime":"0","endTime":"0","summary":"06月16日, 映恩生物-B股价跌4.54%，报收261.00元，成交金额8724.0万元，换手率0.38%，振幅7.10%，量比0.67。映恩生物-B今日主力资金净流出167.7万元，上一交易日主力净流入71.6万元。该股近5个交易日上涨8.75%，主力资金累计净流入1063.1万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入505.8万元，其中净流入天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250616172443a4abbd4d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250616172443a4abbd4d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","09606"],"gpt_icon":0},{"id":"2543681110","title":"医药生物IPO“港漂”热潮：三大热门创新药成焦点，恒瑞医药4个月便实现A+H","url":"https://stock-news.laohu8.com/highlight/detail?id=2543681110","media":"时代周报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2543681110?lang=zh_cn&edition=full","pubTime":"2025-06-13 19:50","pubTimestamp":1749815428,"startTime":"0","endTime":"0","summary":"部分企业“弃A转港”，或为这波港股医药生物IPO热潮添一把火。排队IPO企业方面，截至今年5月31日，港股医药生物IPO申报企业共有20家。医药生物企业扎堆赴港IPO，或与A股IPO审核趋严有关。未盈利医药生物企业扎堆赴港IPO，与港交所创新性推出的18A上市规则有关。例如，恒瑞医药、派格生物、觅瑞等均在招股书中明确提出“出海”计划。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250613195043951b08b8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250613195043951b08b8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","06978","01276","BK1161","02561","BK1191","09606"],"gpt_icon":1},{"id":"1106617128","title":"一周港股牛熊榜 | 生物医药股涨势如虹，绿叶制药全周涨超33%居榜首，晶泰控股涨超28%；半导体股上海复旦承压，全周跌9.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=1106617128","media":"老虎資訊","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1106617128?lang=zh_cn&edition=full","pubTime":"2025-06-13 17:15","pubTimestamp":1749806141,"startTime":"0","endTime":"0","summary":"生物医药股本周涨势亮眼， $绿叶制药$本周升33.33%居榜首， $晶泰控股$ 涨超28%。完善基本医疗保险药品目录调整机制，制定出台商业健康保险创新药品目录，更好满足人民群众多层次用药保障需求。5月下旬，中国创新药企再次闪耀ASCO，共有71项原创性研究成果入选口头发言环节。最常见不良事件为胃肠道和血液学毒性，临床管理良好。$上海复旦$ 本周跌9.45%，消息面上，中芯国际、华虹半导体此前发布的二季度指引谨慎。","market":"hk","thumbnail":"https://community-static.tradeup.com/news/6b12b30d7cf0af9a2b6d2683230cd48c","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/6b12b30d7cf0af9a2b6d2683230cd48c"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01385","02858","02186","02865","00467","02570","HSI","HSTECH","HSCEI","02228","09606"],"gpt_icon":1},{"id":"2542584991","title":"24家药企股价翻倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2542584991","media":"医药研究社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2542584991?lang=zh_cn&edition=full","pubTime":"2025-06-11 20:21","pubTimestamp":1749644478,"startTime":"0","endTime":"0","summary":"截至6月3日，今年A股和H股医药板块上涨明显，约70%企业股价上涨，多家药企股价实现翻倍增长。据药智网统计和铂医药、舒泰神、加科思、荣昌生物、三生制药、一品红等24家公司股价在今年实现翻倍式上涨。其中德琪医药股价上涨5倍多，成为今年医药行业的“涨幅冠军”。多数创新药企业仍处于未盈利状态，未来管线的进展将大幅影响其股价的涨跌。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250611202857a4a383f7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250611202857a4a383f7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06996","688336","06622","688068","09995","01530","09606","02142","01672","688331","688382","02171","BK0239","01167"],"gpt_icon":1},{"id":"2542302057","title":"映恩生物-B06月11日主力净流出240.3万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2542302057","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2542302057?lang=zh_cn&edition=full","pubTime":"2025-06-11 16:15","pubTimestamp":1749629723,"startTime":"0","endTime":"0","summary":"06月11日, 映恩生物-B股价跌0.74%，报收269.40元，成交金额9129.7万元，换手率0.39%，振幅6.19%，量比0.65。映恩生物-B今日主力资金净流出240.3万元，上一交易日主力净流入1150.0万元。该股近5个交易日上涨24.20%，主力资金累计净流入1221.8万元；近20日主力资金累计净流入487.7万元，其中净流入天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250611173057a4a3483d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250611173057a4a3483d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09606","BK1161"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.dualitybiologics.com","stockEarnings":[{"period":"1week","weight":0.0876},{"period":"1month","weight":0.5276},{"period":"3month","weight":0.68},{"period":"6month","weight":2.8076},{"period":"ytd","weight":2.8076}],"compareEarnings":[{"period":"1week","weight":0.0227},{"period":"1month","weight":0.0526},{"period":"3month","weight":0.1615},{"period":"6month","weight":0.2639},{"period":"1year","weight":0.5018},{"period":"ytd","weight":0.2743}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"映恩生物是一家主要从事临床阶段生物制药的投资控股公司。该公司致力于为癌症和自身免疫性疾病等患者研发抗体偶联药物（ADC）创新药物。该公司的主要候选药物产品包括DB-1303/BNT323、DB-1311/BNT324、DB-1310、DB-1305/BNT325、DB-1419和DB-2304。该公司的产品主要用于靶向治疗子宫内膜癌（EC）、乳腺癌（BC）、小细胞肺癌（SCLC）、去势抵抗性前列腺癌（CRPC）、食管鳞状细胞癌（ESCC）及头颈部鳞状细胞癌（HNSCC）。该公司主要在国内和国外市场开展业务。","exchange":"SEHK","name":"映恩生物-B","nameEN":"DUALITYBIO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.4","shortVersion":"4.34.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"映恩生物-B(09606)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供映恩生物-B(09606)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"映恩生物-B,09606,映恩生物-B股票,映恩生物-B股票老虎,映恩生物-B股票老虎国际,映恩生物-B行情,映恩生物-B股票行情,映恩生物-B股价,映恩生物-B股市,映恩生物-B股票价格,映恩生物-B股票交易,映恩生物-B股票购买,映恩生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"映恩生物-B(09606)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供映恩生物-B(09606)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}